Navigation Links
Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
Date:9/2/2010

CARY, N.C., Sept. 2 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), is launching a series of scientific seminars, "An Accelerated Path to Proof-of-Concept in Drug Development," designed to help pharmaceutical and biotechnology researchers learn the latest innovations in Phase I and IIa clinical trial designs. The sessions will familiarize attendees with techniques and study designs to save time and money when bringing new drugs to market. The seven-city series starts on September 15 in Princeton, N.J., and ends on October 21 in San Diego.

"We know that pharmaceutical and biotechnology companies are under increased pressure to get drugs to market as soon as possible. Identifying viable drug candidates quickly allows resources to be used more strategically," said Dr. Troy McCall, CEO of Cetero Research. "Through this seminar series, we can share our expertise and best practices in accelerating the drug development process. Some of the techniques we will be discussing have been shown to cut clinical trial timelines in half and reduce costs by more than 10 percent."

The seminars will focus on three topics: combined Phase I and IIa studies to accelerate proof-of-concept, biomarker fit-for-purpose assays and advanced population PK/PD modeling/analysis. Industry experts will share information and real-life case studies about the accelerated proof-of-concept (AcPOC) study designs and how to select the appropriate level of validation for biomarker assays to ensure that studies meet the current guidance. In addition, Cetero executives will discuss lessons learned from conducting more than 10,000 clinical pharmacology studies in a range of therapeutic areas, working with both healthy participants and patient populations.

"Our case studies demonstrate how the AcPOC study design can combine multiple trials – including single ascending dose (SAD), multiple ascending dose (MAD), preliminary interaction and proof-of-concept (POC) – into one study," said Dr. Graham Wood, President of Clinical Operations for Cetero's Toronto and Miami facilities and one of the speakers in the series. "In one allergy study for a major pharmaceutical company, we went from first patient, first visit, to top-line POC results in just 16 weeks, instead of the average 32 weeks. The savings in time and money, as well as the ability to get actionable data earlier, are major advantages for our sponsors in today's environment."

Each seminar will last approximately two hours and feature three presentations with question and answer sessions. The series schedule is as follows:

  • September 15 — Princeton, N.J.
  • September 29 — Raleigh, N.C.
  • October 7 — Chicago
  • October 12 — Boston
  • October 13 — Philadelphia
  • October 20 — San Francisco
  • October 21 — San Diego

For more information about Cetero's seminar series or to register for a session, please visit www.cetero.com/acpocseminar, email rsvp@cetero.com or call 877-7CETERO.

About Cetero Research

Cetero Research is the leading early-stage contract research organization (CRO). With more than 25 years of experience from its founding companies, Cetero has conducted more than 10,000 clinical pharmacology studies – more than any other CRO. Cetero's proven track record allows the company to provide flexible and high-quality drug-development services. The company's time-tested systems produce consistent and reliable data clients can trust. Cetero's clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. For more information, visit www.cetero.com, or call 877.7CETERO.


'/>"/>
SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Leads Industry in Human Allergy Models
2. St. Jude Childrens Research Hospital Doctors and Scientists Team up to Fight Childhood Cancer
3. Bend Research Receives Patent for Preparing Spray-Dried Drug Dispersions Using Pressure Nozzles
4. Society of Interventional Radiology Supports Research for New M.S. Treatments
5. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
6. Embryonic Stem Cell Research in the Toilet, According to Arthritis Treatment Center
7. Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
8. International Research Team Closes In On Cause of Common Form of Muscular Dystrophy
9. Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets
10. CVS Caremark Behavioral Change Research Partnership Presents Ongoing Research at Center for Disease Control Symposium
11. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Pa. , Dec. 9, 2016 Department ... announced temporary regulations for medical marijuana dispensaries under Act ... Pennsylvania Bulletin , and are now available online ... is needed in the plan for operation; process for ... dispensary; as well as where the dispensary facilities can ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... Patient warming ... of blood during surgeries, lowering the risks of neurological disorders ... of SSIs. The patient warming systems can be segmented into ... benefits in turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... Mediaplanet today ... for organ transplantation while encouraging readers to sign up as an organ donor for ... organ transplant. , An organ donor can save up to 8 saves through ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated ... new solution for Emergency Departments (ED) has been added to their portfolio. Housed ... examination rooms, and with a simplified pallet of information available to the patient, ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... program through the Pennsylvania Cable Network (PCN) during the summer of 2016. The ... Implementation Grant provided by the United States Department of Health and Human Services ...
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... ... awarded accreditation with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the ... with advanced care and patient safety. Only a few hospitals and facilities have ...
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
Breaking Medicine News(10 mins):